Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695502 vs Avastin in advanced nonsquamous NSCLC
NCT02272413Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of BI 695502 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Best Overall Response Rate at 18 weeks. Started Jul 2015; status: completed.
02
Drugs
BI 695502
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02272413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272413.